Información de la revista
Lo más citado
234
A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Sven M. Francque, Arun J. Sanyal, Fasiha Kanwal, Diana Romero, Manal F. Abdelmalek, ... NAFLD Nomenclature consensus group
Ann Hepatol. 2024;29:101133
234
Acceso a texto completo
10
MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney diseaseZiyan Pan, Moutaz Derbala, Khalid AlNaamani, Hasmik Ghazinian, Jian-Gao Fan, Mohammed Eslam
Ann Hepatol. 2024;29:101512
10
Acceso a texto completo
9
Alcohol-associated liver disease: Epidemiology and managementHelena Hernández-Évole, Natalia Jiménez-Esquivel, Elisa Pose, Ramón Bataller
Ann Hepatol. 2024;29:101162
9
Acceso a texto completo
8
Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: An updated meta-analysisWasit Wongtrakul, Natthinee Charatcharoenwitthaya, Phunchai Charatcharoenwitthaya
Ann Hepatol. 2024;29:101288
8
Acceso a texto completo
6
Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agentsAndrea del Carmen Maldonado-Rojas, Julia María Zuarth-Vázquez, Misael Uribe, Varenka J Barbero-Becerra
Ann Hepatol. 2024;29:101182
6
Acceso a texto completo
5
Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018Tongtong Wang, Yuzhi Xi, Annaswamy Raji, Michael Crutchlow, Gail Fernandes, Samuel S Engel, Xiao Zhang
Ann Hepatol. 2024;29:101154
5
Acceso a texto completo
5
Global prevalence of occult HBV infection in children and adolescents: A systematic review and meta-analysisJiaying Wu, Jiayao He, Hongmei Xu
Ann Hepatol. 2024;29:101158
5
Acceso a texto completo
5
Influence of socioeconomic factors on liver transplant survival outcomes in patients with autoimmune liver disease in the United StatesLeandro Sierra, Ana Marenco-Flores, Romelia Barba, Daniela Goyes, Bryan Ferrigno, Wilfor Diaz, Esli Medina-Morales, Behnam Saberi, ... Alan Bonder
Ann Hepatol. 2024;29:101283
5
Acceso a texto completo
5
From NAFLD to MASLD: When metabolic comorbidity mattersShan Hong, Lei Sun, Yiwei Hao, Ping Li, Yuling Zhou, Xiuxia Liang, Julong Hu, Hongshan Wei
Ann Hepatol. 2024;29:101281
5
Acceso a texto completo
4
Assessment of TLL1 variant and risk of hepatocellular carcinoma in Latin Americans and EuropeansSiyu Fu, Dhamina Karim, Jhon Prieto, Domingo Balderramo, Javier Diaz Ferrer, Angelo Z. Mattos, Marco Arrese, Enrique Carrera, ... Andre Boonstra
Ann Hepatol. 2024;29:101181
4
Acceso a texto completo